Development Pipeline

	Preclinical	Phase I	Phase II	Phase III	Marketed
Pixantrone	The U.S. Food and Drug Administration (FDA) accepted for standard review our New Drug Application (NDA) with a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010.
OPAXIO™
Brostallicin

	Preclinical	Phase I	Phase II	Phase III	Marketed
Novel Platinum Complexes

Patients Respond to Cancer Therapy in Different Ways. So Do We.

There are different kinds of cancer. That’s why we develop different kinds of cancer therapy, with the goal of making cancer more treatable for individual patients.

Our cancer drug development pipeline includes a biologically enhanced taxane, a new compound designed to treat cancers normally treated with anthracyclines, and a DNA minor groove binding agent—each of which has the potential to treat a variety of cancer types.

Current Status

We are focused on gaining approvals for our two phase III product candidates, pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma, and OPAXIO in maintenance of ovarian cancer following complete remission after first-line treatment. We have one product in phase II clinical development, and other candidates in preclinical research. These products may address the therapeutic limitations of conventional cancer therapies.